{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:33:30Z","timestamp":1782552810305,"version":"3.54.5"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the epidemiological association between serum insulin-like growth factor-1 (IGF-I) levels and the risk of prostate cancer, in order to provide evidence-based support for risk stratification and early prevention of prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In accordance with the PRISMA statement, major domestic and international databases were systematically searched. Cohort studies, case-control studies, and Mendelian randomization studies reporting the relationship between serum IGF-I and prostate cancer risk were included. A random-effects model was used to combine effect estimates, assess heterogeneity, and perform subgroup analysis and meta-regression. Sensitivity analysis and publication bias tests were used to evaluate the robustness of the results, and the GRADE system was used to assess the quality of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16 studies involving multiple countries were included. The combined analysis showed that higher serum IGF-I levels were associated with an increased risk of prostate cancer (OR = 1.10, 95% CI: 1.02\u20131.18, P = 0.0136), with moderate heterogeneity (I\u00b2=50.6%). Subgroup analysis indicated that the association was more prominent in studies published in the last decade and in nested case-control designs, but heterogeneity was higher in large-sample and multicenter studies. Meta-regression analysis did not find that mean age or IGF-I levels significantly explained the heterogeneity. Sensitivity and publication bias analyses both supported the robustness of the main conclusion, and the GRADE assessment indicated moderate quality of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher serum IGF-I levels are epidemiologically associated with an increased risk of prostate cancer, but the dose-response relationship is still unclear, and the correlation is susceptible to study characteristics and confounding factors. IGF-I is expected to be a potential biomarker for prostate cancer risk stratification. It is recommended that more high-quality studies be conducted in the future to verify its clinical application value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251174259.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1730382","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:55Z","timestamp":1767940795000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum insulin-like growth factor-1 and epidemiological evidence of the risk of prostate cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Bo","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e33456","DOI":"10.1097\/MD.0000000000033456","article-title":"Mendelian randomization study of serum and urine biomarkers and risk of prostate cancer","volume":"104","author":"Lin","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e75342","DOI":"10.7759\/cureus.75342","article-title":"Serum insulin, insulin-like growth factor-1, testosterone and lipid profile levels in benign prostatic hyperplasia and prostate cancer at diagnosis","volume":"16","author":"Khan","year":"2024","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6810","article-title":"Two prostate cancer\u2212associated polymorphisms in the 3\u2019UTR of IGF1R influences prostate cancer susceptibility by affecting miRNA binding","author":"Wang","year":"2018","journal-title":"Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1385\/ENDO:12:2:197","article-title":"Growth hormone and aging","volume":"12","author":"Rosen","year":"2000","journal-title":"Endocrine"},{"key":"B5","first-page":"79","article-title":"Milk and linear growth: programming of the IGF-I axis and implication for health in adulthood","volume-title":"Nestl\u00e9 Nutrition Institute Workshop Series","author":"Martin","year":"2011"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20589","article-title":"Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer","volume":"67","author":"Li","year":"2007","journal-title":"Prostate"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-07-2694","article-title":"Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A prospective multiethnic study","volume":"17","author":"Borugian","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.23.1910","article-title":"Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study","volume":"92","author":"Stattin","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.911","article-title":"Insulin-like growth factor 1 and prostate cancer risk: a population-based, case\u2013control study","volume":"90","author":"Wolk","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1601","article-title":"Circulating insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in PSA-detected prostate cancer: the large case control study ProtecT","volume":"72","author":"Rowlands","year":"2012","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11631","article-title":"Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study","volume":"108","author":"Oliver","year":"2004","journal-title":"Int J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0507","article-title":"Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-1 and its binding protein, and risk of prostate and breast cancer","volume":"19","author":"Gu","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0113","article-title":"Reassessing the association between circulating Vitamin D and IGFBP-3: observational and Mendelian randomization estimates from independent sources","volume":"27","author":"Tan","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac061","article-title":"Circulating insulin-like growth factor 1\u2013related biomarkers and risk of lethal prostate cancer","volume":"6","author":"Ma","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11628","article-title":"Prospective study of insulin-like growth factor\u2013I, IGF-binding protein\u20133 and risk of prostate cancer","volume":"108","author":"Hallmans","year":"2004","journal-title":"Int J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24921","article-title":"Insulin-like growth factors and prostate cancer risk: a population-based nested case\u2013control study","volume":"126","author":"Mucci","year":"2010","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-013-3135-3","article-title":"Metabolisches syndrom und prostatakarzinom","volume":"52","author":"Schmitz-Dr\u00e4ger","year":"2013","journal-title":"Urologe"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq210","article-title":"A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians","volume":"19","author":"Schumacher","year":"2010","journal-title":"Hum Mol Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1730382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:39:57Z","timestamp":1767940797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1730382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1730382"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1730382","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"article-number":"1730382"}}